Literature DB >> 15262463

Evaluating the quality of life of patients with restless legs syndrome.

Linda Abetz1, Richard Allen, Alain Follet, Tinna Washburn, Christopher Earley, Jeff Kirsch, Helen Knight.   

Abstract

BACKGROUND: The primary morbidities of restless legs syndrome (RLS) involve sleep loss, extreme discomfort, and disruption of normal activities. Although the condition is not life-threatening, assessing the disease burden and the impact of RLS on quality of life (QOL) is critical for evaluating treatment benefits.
OBJECTIVE: The purpose of this study was to assess the impact of RLS on QOL.
METHODS: In this subanalysis of a specific validation study, the SF-36 (Medical Outcomes Study 36-Item Short Form health survey) was administered to 85 patients with primary RLS who had been referred to a sleep-medicine clinic. The scores were compared with published norms for the general population (N = 2474).
RESULTS: The majority (63.5%) of RLS patients were women; the mean (SD) age was 62.4 (14.0) years; 67.1% of patients experienced RLS symptoms almost daily. The RLS group, particularly patients with more severe RLS, reported significant deficits (10-40 points on 100-points scales) in physical functioning, bodily pain, role functioning, mental health, general health, and vitality compared with the general population. The RLS sample had significantly lower scores (worse QOL) on all 8 scales of the SF-36 compared with patients with hypertension (P<0.01); compared with patients with other cardiovascular conditions (ie, congestive heart failure, myocardial infarction within the past year, and angina), the RLS group had lower scores on 6 of the 8 scales. RLS patients had lower scores on 7 of 8 scales compared with diabetes patients, and on 4 of 8 scales compared with osteoarthritis patients.
CONCLUSIONS: Comparison of the SF-36 scores of patients with RLS and the normative general population suggests that the disorder has a significant impact on patient QOL.

Entities:  

Mesh:

Year:  2004        PMID: 15262463     DOI: 10.1016/s0149-2918(04)90136-1

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  71 in total

1.  The burden of restless legs syndrome: an assessment of work productivity, sleep, psychological distress, and health status among diagnosed and undiagnosed individuals in an internet-based panel.

Authors:  Sheri Fehnel; Laurie Zografos; Tammy Curtice; Hemal Shah; Lori McLeod
Journal:  Patient       Date:  2008-07-01       Impact factor: 3.883

2.  Restless Legs Syndrome and Sleep-Wake Disturbances in Pregnancy.

Authors:  Galit Levi Dunietz; Lynda D Lisabeth; Kerby Shedden; Q Afifa Shamim-Uzzaman; Alexandra S Bullough; Mark C Chames; Marc F Bowden; Louise M O'Brien
Journal:  J Clin Sleep Med       Date:  2017-07-15       Impact factor: 4.062

3.  Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study.

Authors:  Heike Benes; Wolfgang Mattern; Ines Peglau; Tillmann Dreykluft; Lars Bergmann; Corinna Hansen; Ralf Kohnen; Norbert Banik; S W Schoen; Magdolna Hornyak
Journal:  J Neurol       Date:  2010-12-28       Impact factor: 4.849

Review 4.  Prevalence of restless legs syndrome in North American and Western European populations: a systematic review.

Authors:  Kim E Innes; Terry Kit Selfe; Parul Agarwal
Journal:  Sleep Med       Date:  2011-07-12       Impact factor: 3.492

5.  A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome.

Authors:  Clete A Kushida; Arthur S Walters; Philip Becker; Stephen G Thein; A Thomas Perkins; Thomas Roth; Daniel Canafax; Ronald W Barrett
Journal:  Sleep       Date:  2009-02       Impact factor: 5.849

Review 6.  [Restless legs syndrome, periodic limb movements, and psychopharmacology].

Authors:  S Cohrs; A Rodenbeck; M Hornyak; D Kunz
Journal:  Nervenarzt       Date:  2008-11       Impact factor: 1.214

7.  Functional impairment in adult sleepwalkers: a case-control study.

Authors:  Regis Lopez; Isabelle Jaussent; Sabine Scholz; Sophie Bayard; Jacques Montplaisir; Yves Dauvilliers
Journal:  Sleep       Date:  2013-03-01       Impact factor: 5.849

8.  Depressive disorders in restless legs syndrome: epidemiology, pathophysiology and management.

Authors:  Magdolna Hornyak
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

9.  BTBD9 and dopaminergic dysfunction in the pathogenesis of restless legs syndrome.

Authors:  Shangru Lyu; Atbin Doroodchi; Hong Xing; Yi Sheng; Mark P DeAndrade; Youfeng Yang; Tracy L Johnson; Stefan Clemens; Fumiaki Yokoi; Michael A Miller; Rui Xiao; Yuqing Li
Journal:  Brain Struct Funct       Date:  2020-05-28       Impact factor: 3.270

10.  [Socioeconomic relevance of the idiopathic restless legs syndrome (RLS) in Germany: cost-of-illness study].

Authors:  Sandra Nelles; Juliane Köberlein; Christine Grimm; David Pittrow; Wilhelm Kirch; Reinhard Rychlik
Journal:  Med Klin (Munich)       Date:  2009-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.